Diagnostic Value of Presepsin for Sepsis: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 WEIGuo-hua ¹ , JIANGMing-yong ² , JIANGLa-mei ³

1. Emergency Department, People's Hospital of Jianyang City, Jianyang 641400, China;
2. Emergency Department, People's Hospital of Yuechi County, Yuechi 638300, China;
3. Department of General Internal Medicine, the Affiliated Hospital of Chengdu Sport University, Chengdu 610041, China;

Corresponding?author：

Keywords：

Presepsin; Sepsis; Diagnostic test; Meta-analysis

DOI：

10.7507/1672-2531.20160046

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the diagnostic value of Presepsin for sepsis. Methods We searched databases including PubMed, EMbase, Web of Science, WanFang, VIP and CNKI from inception to June 2015 to collect diagnostic tests related to Presepsin for spesis. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies by QUADAS-2 tool. Then, meta-analysis was performed by Stata 13.0 software. Results A total of 19 studies involving 4140 samples were included. The results of meta-analysis showed that:the pooled sensitivity (Sen) and specificity (Spe) were 0.85 (95%CI 0.79 to 0.90) and 0.83 (95%CI 0.76 to 0.87), respectively. The area under the summary receiver operating characteristic (SROC) curve was 0.91 (95%CI 0.88 to 0.93). Conclusion Presepsin shows high diagnostic value for sepsis as a novel biomarker. Due to the limited quality of the included studies, more high quality studies are needed to verify the above conclusion.

Citation： WEIGuo-hua, JIANGMing-yong, JIANGLa-mei. Diagnostic Value of Presepsin for Sepsis: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(3): 286-291. doi: 10.7507/1672-2531.20160046 Copy

1.	Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003, 348(16):1546-1554.
2.	Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992, 101(6):1644-1655.
3.	Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta, 2015, 440:97-103.
4.	Sandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol, 2014, 10(10):1349-1356.
5.	Mussap M, Noto A, Fravega M, et al. Soluble CD14 subtype Presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis:new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med, 2011, 24(Suppl 2):12-14.
6.	Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med, 2014, 5(1):16-19.
7.	鄔蘭, 張永, 曾憲濤. QUADAS-2在診斷準確性研究的質量評價工具中的應用. 湖北醫藥學院學報, 2013, (3):201-208.
8.	張俊, 徐志偉, 李克. 診斷性試驗Meta分析的效應指標評價. 中國循證醫學雜志, 2013, 13(7):890-895.
9.	Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414):557-560.
10.	Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol, 2005, 58(10):982-990.
11.	Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 2005, 58(9):882-893.
12.	余建, 邵強, 王權, 等. 聯合檢測Presepsin、降鈣素原和C反應蛋白對膿毒癥早期診斷及預后評估的價值. 臨床檢驗雜志, 2014, 32(3):200-203.
13.	楊愛龍, 陳曦, 高宏偉, 等. 膿毒癥的診斷和預后評估中Presepsin的臨床價值. 中華檢驗醫學雜志, 2015, 38(2):124-127.
14.	蘇明環, 壽松濤. 血Presepsin對膿毒癥診斷及病情判斷的臨床價值. 臨床檢驗雜志, 2014, 32(2):106-111.
15.	高楊. 急性創傷患者早期監測Presepsin的臨床意義. 天津:天津醫科大學, 2014:4-22.
16.	陳義坤, 趙明, 張浩. 膿毒癥患者血漿Presepsin水平檢測的臨床意義. 實用醫學雜志, 2014, (20):3256-3258.
17.	Vodnik T, Kaljevic G, Tadic T, et al. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med, 2013, 51(10):2053-2062.
18.	Ulla M, Pizzolato E, Lucchiari M, et al. Diagnostic and prognostic value of Presepsin in the management of sepsis in the emergency department:a multicenter prospective study. Crit Care, 2013, 17(4):R168.
19.	Takahashi G, Shibata S, Ishikura H, et al. Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation:a prospective, multicentre, observational study. Eur J Anaesthesiol, 2015, 32(3):199-206.
20.	Romualdo LGDG, Torrella PE, Gonzalez MV, et al. Diagnostic accuracy of Presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clin Biochem, 2014, 47(7-8):505-508.
21.	Nakamura Y, Ishikura H, Nishida T, et al. Usefulness of Presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol, 2014, 14:88.
22.	Liu B, Chen YX, Yin Q, et al. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care, 2013, 17(5):R244.
23.	Kweon OJ, Choi JH, Park SK, et al. Usefulness of Presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J Crit Care, 2014, 29(6):965-970.
24.	Ishikura H, Nishida T, Murai A, et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation:a prospective single-center observational study. Crit Care, 2014, 18(1):R19.
25.	Godnic M, Stubjar D, Skvarc M, et al. Diagnostic and prognostic value of sCD14-ST-Presepsin for patients admitted to hospital intensive care unit (ICU). Wien Klin Wochenschr, 2015, 127(13):521-527.
26.	Endo S, Suzuki Y, Takahashi G, et al. Usefulness of Presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother, 2012, 18(6):891-897.
27.	Cakir Madenci O, Yakupoglu S, Benzonana N, et al. Evaluation of soluble CD14 subtype (Presepsin) in burn sepsis. Burns, 2014, 40(4):664-669.
28.	Brenner T, Fleming T, Uhle F, et al. Methylglyoxal as a new biomarker in patients with septic shock:an observational clinical study. Crit Care, 2014, 18(6):683.
29.	Behnes M, Bertsch T, Lepiorz D, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (Presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care, 2014, 18(5):507.
30.	Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of Presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother, 2011, 17(6):764-769.
31.	Zhang X, Liu D, Liu YN, et al. The accuracy of Presepsin (sCD14-ST) for the diagnosis of sepsis in adults:a meta-analysis. Crit Care, 2015, 19:323.
32.	Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis:a systematic review and meta-analysis. Lancet Infect Dis, 2013, 13(5):426-435.
33.	Wu YP, Li JB, Deng XM. Diagnostic value of plasma soluble triggering receptor expressed on myeloid cells-1 for sepsis:A systematic review. J Evid Based Med, 2013, 13(4):425-430.
34.	Li S, Huang X, Chen Z, et al. Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection:a meta-analysis. Int J Infect Dis, 2013, 17(1):e12-23.

1. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med, 2003, 348(16):1546-1554.
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992, 101(6):1644-1655.
3. Prucha M, Bellingan G, Zazula R. Sepsis biomarkers. Clin Chim Acta, 2015, 440:97-103.
4. Sandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol, 2014, 10(10):1349-1356.
5. Mussap M, Noto A, Fravega M, et al. Soluble CD14 subtype Presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis:new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med, 2011, 24(Suppl 2):12-14.
6. Zou Q, Wen W, Zhang XC. Presepsin as a novel sepsis biomarker. World J Emerg Med, 2014, 5(1):16-19.
7. 鄔蘭, 張永, 曾憲濤. QUADAS-2在診斷準確性研究的質量評價工具中的應用. 湖北醫藥學院學報, 2013, (3):201-208.
8. 張俊, 徐志偉, 李克. 診斷性試驗Meta分析的效應指標評價. 中國循證醫學雜志, 2013, 13(7):890-895.
9. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003, 327(7414):557-560.
10. Reitsma JB, Glas AS, Rutjes AW, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol, 2005, 58(10):982-990.
11. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol, 2005, 58(9):882-893.
12. 余建, 邵強, 王權, 等. 聯合檢測Presepsin、降鈣素原和C反應蛋白對膿毒癥早期診斷及預后評估的價值. 臨床檢驗雜志, 2014, 32(3):200-203.
13. 楊愛龍, 陳曦, 高宏偉, 等. 膿毒癥的診斷和預后評估中Presepsin的臨床價值. 中華檢驗醫學雜志, 2015, 38(2):124-127.
14. 蘇明環, 壽松濤. 血Presepsin對膿毒癥診斷及病情判斷的臨床價值. 臨床檢驗雜志, 2014, 32(2):106-111.
15. 高楊. 急性創傷患者早期監測Presepsin的臨床意義. 天津:天津醫科大學, 2014:4-22.
16. 陳義坤, 趙明, 張浩. 膿毒癥患者血漿Presepsin水平檢測的臨床意義. 實用醫學雜志, 2014, (20):3256-3258.
17. Vodnik T, Kaljevic G, Tadic T, et al. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin Chem Lab Med, 2013, 51(10):2053-2062.
18. Ulla M, Pizzolato E, Lucchiari M, et al. Diagnostic and prognostic value of Presepsin in the management of sepsis in the emergency department:a multicenter prospective study. Crit Care, 2013, 17(4):R168.
19. Takahashi G, Shibata S, Ishikura H, et al. Presepsin in the prognosis of infectious diseases and diagnosis of infectious disseminated intravascular coagulation:a prospective, multicentre, observational study. Eur J Anaesthesiol, 2015, 32(3):199-206.
20. Romualdo LGDG, Torrella PE, Gonzalez MV, et al. Diagnostic accuracy of Presepsin (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clin Biochem, 2014, 47(7-8):505-508.
21. Nakamura Y, Ishikura H, Nishida T, et al. Usefulness of Presepsin in the diagnosis of sepsis in patients with or without acute kidney injury. BMC Anesthesiol, 2014, 14:88.
22. Liu B, Chen YX, Yin Q, et al. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care, 2013, 17(5):R244.
23. Kweon OJ, Choi JH, Park SK, et al. Usefulness of Presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J Crit Care, 2014, 29(6):965-970.
24. Ishikura H, Nishida T, Murai A, et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation:a prospective single-center observational study. Crit Care, 2014, 18(1):R19.
25. Godnic M, Stubjar D, Skvarc M, et al. Diagnostic and prognostic value of sCD14-ST-Presepsin for patients admitted to hospital intensive care unit (ICU). Wien Klin Wochenschr, 2015, 127(13):521-527.
26. Endo S, Suzuki Y, Takahashi G, et al. Usefulness of Presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother, 2012, 18(6):891-897.
27. Cakir Madenci O, Yakupoglu S, Benzonana N, et al. Evaluation of soluble CD14 subtype (Presepsin) in burn sepsis. Burns, 2014, 40(4):664-669.
28. Brenner T, Fleming T, Uhle F, et al. Methylglyoxal as a new biomarker in patients with septic shock:an observational clinical study. Crit Care, 2014, 18(6):683.
29. Behnes M, Bertsch T, Lepiorz D, et al. Diagnostic and prognostic utility of soluble CD 14 subtype (Presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care, 2014, 18(5):507.
30. Shozushima T, Takahashi G, Matsumoto N, et al. Usefulness of Presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother, 2011, 17(6):764-769.
31. Zhang X, Liu D, Liu YN, et al. The accuracy of Presepsin (sCD14-ST) for the diagnosis of sepsis in adults:a meta-analysis. Crit Care, 2015, 19:323.
32. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis:a systematic review and meta-analysis. Lancet Infect Dis, 2013, 13(5):426-435.
33. Wu YP, Li JB, Deng XM. Diagnostic value of plasma soluble triggering receptor expressed on myeloid cells-1 for sepsis:A systematic review. J Evid Based Med, 2013, 13(4):425-430.
34. Li S, Huang X, Chen Z, et al. Neutrophil CD64 expression as a biomarker in the early diagnosis of bacterial infection:a meta-analysis. Int J Infect Dis, 2013, 17(1):e12-23.

Chinese Journal of Evidence-Based Medicine

Diagnostic Value of Presepsin for Sepsis: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content